EUVIMEDObjevte EUVIMED
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen access · CC BY-NC-ND 4.0

CT ‐ P39 Compared With Reference Omalizumab in Chronic Spontaneous Urticaria: Results From a Double‐Blind, Randomized, Active‐Controlled, Phase 3 Study

Sarbjit S Saini, Marcus Maurer iD, Yevgeniya Dytyatkovska, Ewa Springer, Maria Ratkova, Borislava Krusheva, Chun Wook Park, Grazyna Pulka, Marta Chełmińska, Adam Reich, Sunghyun Kim, Keumyoung Ahn and 5 more

Allergy · 2025

DOI: 10.1111/all.16446 ↗

At a glance

Randomisierte kontrollierte Studie in Allergy, 2025. Written by Sarbjit S Saini and 16 co-authors. Institution: Johns Hopkins Asthma & Allergy Center, Baltimore, Maryland, USA. Major MEDLINE topics: Omalizumab, Chronic Urticaria, Anti-Allergic Agents, Biosimilar Pharmaceuticals. Cited 30 times so far (Crossref); 25 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Celltrion Inc, Celltrion.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

This study compared the therapeutic equivalence of CT‐P39 (an omalizumab biosimilar) and EU‐approved reference omalizumab (ref‐OMA) in patients with chronic spontaneous urticaria.

Methods

This double‐blind, randomized, active‐controlled Phase 3 study (NCT04426890) included two 12‐week treatment periods (TPs). In TP1, patients received CT‐P39 300 mg, ref‐OMA 300 mg, CT‐P39 150 mg, or ref‐OMA 150 mg. In TP2, patients treated with ref‐OMA 300 mg were rerandomized to CT‐P39 300 mg or ref‐OMA 300 mg; patients initially randomized to CT‐P39 300 mg continued this regimen; and patients initially randomized to CT‐P39 or ref‐OMA 150 mg received 300 mg dosing with the same drug. The primary endpoint for the assessment of therapeutic equivalence of CT‐P39 300 mg and ref‐OMA 300 mg was change from baseline in weekly itch severity score (ISS7) at week 12.

Results

In TP1, 619 patients were randomized (CT‐P39 300 mg, n = 204; ref‐OMA 300 mg, n = 205; CT‐P39 150 mg, n = 107; ref‐OMA 150 mg, n = 103). Equivalence was demonstrated between CT‐P39 300 mg and ref‐OMA 300 mg for mean change from baseline in ISS7 at week 12; confidence intervals (CIs) were within predefined equivalence margins: global analysis: treatment difference 0.77, 95% CI –0.37 to 1.90; US analysis: treatment difference 0.70, 90% CI –0.22 to 1.63. The proportion of patients experiencing ≥ 1 treatment‐related adverse event was comparable across groups. Secondary efficacy, quality of life, pharmacokinetic, safety, and immunogenicity outcomes were comparable between groups at a given dose level, with no evident impact of switching.

Conclusions

Equivalent efficacy was observed between CT‐P39 and ref‐OMA, with comparable safety also evident.

Subjects

MeSH terms (MEDLINE)

OmalizumabChronic UrticariaAnti-Allergic AgentsBiosimilar PharmaceuticalsHumansFemaleMaleDouble-Blind MethodAdultMiddle AgedTreatment OutcomeSeverity of Illness IndexYoung AdultAgedTherapeutic Equivalency

Author keywords

CT‐P39anti‐IgEbiosimilarchronic spontaneous urticariaomalizumab

Substances

OmalizumabAnti-Allergic AgentsBiosimilar Pharmaceuticals

Authors and institutions

  • Johns Hopkins Asthma & Allergy Center, Baltimore, Maryland, USA.
  • Urticaria Center of Reference and Excellence (UCARE), Institute of Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität Zu Berlin, Berlin, Germany.
  • Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany.
  • Clinical Hospital of Emergency Medical Care of Dniprovska City Council, Dnipro, Ukraine.
  • Specjalistyczny NZOZ Alergologia Plus, Poznań, Poland.
  • Medical Center Hera, Sofia, Bulgaria.

ORCID profiles: Marcus Maurer, Clive Grattan

Funding

  • Celltrion Inc
  • Celltrion

Cite

APA

Saini, S. S., Maurer, M., Dytyatkovska, Y., Springer, E., Ratkova, M., Krusheva, B., Park, C. W., Pulka, G., Chełmińska, M., Reich, A., Kim, S., Ahn, K., Kim, S., Lee, S., Ka, J., Kim, J., & Grattan, C. (2025). CT ‐ P39 Compared With Reference Omalizumab in Chronic Spontaneous Urticaria: Results From a Double‐Blind, Randomized, Active‐Controlled, Phase 3 Study. Allergy. https://doi.org/10.1111/all.16446

Vancouver

Saini SS, Maurer M, Dytyatkovska Y, Springer E, Ratkova M, Krusheva B, et al. CT ‐ P39 Compared With Reference Omalizumab in Chronic Spontaneous Urticaria: Results From a Double‐Blind, Randomized, Active‐Controlled, Phase 3 Study. Allergy. 2025. doi:10.1111/all.16446

BibTeX
@article{Saini2025,
  author = {Saini, Sarbjit S and Maurer, Marcus and Dytyatkovska, Yevgeniya and Springer, Ewa and Ratkova, Maria and Krusheva, Borislava and Park, Chun Wook and Pulka, Grazyna and Chełmińska, Marta and Reich, Adam and Kim, Sunghyun and Ahn, Keumyoung and Kim, Suyoung and Lee, Sewon and Ka, Jieun and Kim, Jongho and Grattan, Clive},
  title = {CT ‐ P39 Compared With Reference Omalizumab in Chronic Spontaneous Urticaria: Results From a Double‐Blind, Randomized, Active‐Controlled, Phase 3 Study},
  journal = {Allergy},
  year = {2025},
  doi = {10.1111/all.16446}
}
Start for free →